Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | QPCT | Q16769 | 1/20 | 0.46 |
| ▸ | FPR3 | P25089 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5100819 | 0.99 | ALDH1A1 (0.51) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL1258720 | 0.87 | ALDH1A1 (0.53) | ALDH1A1MAPTSMN1; SMN2RAB9ATDP1 | |
| SCHEMBL4396662 | 0.86 | KMT2A (0.54) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL8271414 | 0.85 | TDP1 (0.56) | TDP1CA1CA2KMT2AGAA | |
| SCHEMBL8271418 | 0.85 | TDP1 (0.56) | TDP1CA1CA2KMT2AGAA | |
| SCHEMBL31203431 | 0.85 | CA1 (0.64) | TDP1CA1CA2GAALMNA | |
| SCHEMBL8271413 | 0.84 | TDP1 (0.54) | TDP1CA1CA2KMT2AGAA | |
| SCHEMBL4396949 | 0.84 | KMT2A (0.64) | ALDH1A1MAPTSMN1; SMN2CA1CA2 | |
| SCHEMBL4392250 | 0.83 | KMT2A (0.54) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4394067 | 0.82 | LMNA (0.60) | ALDH1A1MAPTSMN1; SMN2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368605-B2 | Variously substituted derivatives of guanidine, and their use as medicines with anti-diabetes and/or anti-obesity activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-05-06 | — | — | US | disclosed |
| US-20060069100-A1 | Variously substituted derivatives of guanidine, and their use as medicines with anti-diabetes and/or anti-obesity activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2006-03-30 | — | — | US | disclosed |
| EP-1575912-A1 | VARIOUSLY SUBSTITUTED DERIVATIVES OF GUANIDINE, AND THEIR USE AS MEDICINES WITH ANTI-DIABETES AND/OR ANTI-OBESITY ACTIVITY | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004054967-A1 | VARIOUSLY SUBSTITUTED DERIVATIVES OF GUANIDINE, AND THEIR USE AS MEDICINES WITH ANTI-DIABETES AND/OR ANTI-OBESITY ACTIVITY | SIGMA TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069100-A1 | Variously substituted derivatives of guanidine, and their use as medicines with anti-diabetes and/or anti-obesity activity | GCKR, GPR119, GCG | ALDH1A1 2247/4885MAPT 3995/4885SMN1; SMN2 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.